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Abstract
Objective—Both subclinical hypothyroidism and the metabolic syndrome have been associated
with increased risk of coronary heart disease events. It is unknown if the prevalence and incidence
of metabolic syndrome is higher as TSH levels increase, or in individuals with subclinical
hypothyroidism. We sought to determine the association between thyroid function and the
prevalence and incidence of the metabolic syndrome in a cohort of older adults.
Design—Data was analyzed from the Health, Aging, and Body Composition Study, a prospective
cohort of 3,075 community-dwelling US adults.
Participants—2,119 participants with measured TSH and data on metabolic syndrome
components were included in the analysis.
Measurements—TSH was measured by immunoassay. Metabolic syndrome was defined per
revised ATP III criteria.
Results—At baseline, 684 participants met criteria for metabolic syndrome. At 6yr follow-up,
incident metabolic syndrome developed in 239 individuals. In fully adjusted models, each unit
increase in TSH was associated with a 3% increase in the odds of prevalent metabolic syndrome
(OR 1.03, 95% CI 1.01–1.06, p=0.02), and the association was stronger for TSH within the normal
range (OR 1.16, 95% CI 1.03–1.30, p=0.02). Subclinical hypothyroidism with a TSH>10mIU/L
was significantly associated with increased odds of prevalent metabolic syndrome (OR 2.3, 95%
CI 1.0–5.0, p=0.04); the odds of incident MetS was similar (OR 2.2), but the confidence interval
was wide (0.6–7.5).
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Conclusions—Higher TSH levels and subclinical hypothyroidism with a TSH>10 mIU/L are
associated with increased odds of prevalent but not incident metabolic syndrome.
Keywords
Thyroid Function; Metabolic Syndrome; Subclinical Hypothyroidism
Introduction
The association between overt hypothyroidism and atherosclerotic cardiovascular disease is
well-described1 and increasing evidence suggests an association exists with milder degrees
of thyroid dysfunction such as subclinical hypothyroidism.2 Several observational studies
have examined the relationship between subclinical hypothyroidism and cardiovascular
disease and mortality with conflicting results;3–6 however, a recent individual participant
data meta-analysis of 11 prospective studies reported a positive association.2 In studies
where an association has been found, the observed relationship persists after adjustment for
traditional risk factors, suggesting an alternative mechanism by which subclinical
hypothyroidism increases cardiovascular risk.2, 5, 6
The metabolic syndrome (MetS), which has been linked to cardiovascular disease and
mortality in the general population,7, 8 is one such potential mechanism. MetS is
characterized by atherogenic dyslipidemia, insulin resistance and hypertension,9 all of which
may be increased in hypothyroid or subclinical hypothyroid states. It is presently unknown if
higher TSH within the euthyroid range or subclinical hypothyroidism is associated with an
increased prevalence and incidence of MetS. Several recent cross-sectional studies have
sought to determine this relationship with conflicting findings.10–14 To date, there have been
no prospective studies on the association between thyroid function and MetS.
Although most individuals at risk for cardiovascular disease are euthyroid, older adults have
a higher prevalence of subclinical hypothyroidism15 and therefore a potential relationship
between elevated TSH and the risk factors characterizing the metabolic syndrome may be
more important to identify in this group. To characterize the association between thyroid
function and the prevalence and incidence of the metabolic syndrome in older adults, we
examined 6 years of follow-up data from the Health, Aging, and Body Composition (Health
ABC) cohort study.
Participants and Methods
Study Population
Data were analyzed from the Health ABC study, a prospective cohort of 3,075 White and
Black community-dwelling persons aged 70–79 at enrollment designed to study body
composition and physical function. Participants were recruited from a random sample of
White Medicare beneficiaries and all age-eligible Black community residents in Pittsburgh,
PA and Memphis, TN. Eligibility criteria included the ability to walk ¼ mile, up 10 stairs
without rest and perform basic activities of daily living independently.16 The institutional
review board at each of the two sites approved of the protocol and all subjects provided
written informed consent.
2799 participants of the cohort had TSH measured from fasting blood samples at the second
year visit. Free thyroxine (FT4) levels were reflexively measured on any participant with a
TSH value of less than 0.1 mIU/L or greater than 7.0 mIU/L.17
We excluded participants with diabetes at baseline (n=632), defined as a self-reported
diagnosis of diabetes, use of diabetes medications, fasting glucose of 7.0 mmol/L or higher,
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or 2-h glucose of 11.1 mmol/L or higher after a 75-g oral glucose load, because they already
exhibit a more complete phenotype of insulin resistance and dyslipidemia than individuals
with the MetS. We further excluded participants on amiodarone (n=5), lithium (n=2), and
antithyroid medications (n=1) due to their variable effects on thyroid function. Individuals
with overt hyperthyroidism (n=4) were excluded as this represented a small number of
participants, and 36 persons were excluded for missing data on the MetS. The final sample
for this analysis was 2,119 participants.
Measurements
Thyroid Hormones—TSH was measured by a central lab at the University of Vermont by
immunoassay (ACS; Chiron Diagnostics Corp, Emeryville, Calif). According to the
manufacturer, the coefficient of variation for TSH was 4.71% at a level of 0.30 mIU/L and
3.64% at a level of 15.85 mIU/L. The normal range for TSH in this assay is 0.35–5.5 mIU/L.
FT4 was measured by competitive immunoassay (ACS; Chiron Diagnostics). The normal
range for FT4 in this assay is 10.3–23.2 pmol/L (0.8–1.8 ng/dL). Categories of thyroid
function were defined as subclinical hyperthyroid (TSH <0.35 mIU/L), euthyroid (TSH
0.35–4.5 mIU/L), mild subclinical hypothyroid (TSH 4.5–9.9 mIU/L, normal FT4), marked
subclinical hypothyroid (TSH 10–20 mIU/L, normal FT4), and overt hypothyroid (TSH>4.5
mIU/L and FT4 < 10.3 pmol/L).
Metabolic Syndrome—Metabolic syndrome was defined per revised NCEP/ATP III
criteria as any 3 of 5 criteria: waist circumference ≥102cm for men or ≥88cm for women,
elevated triglycerides (TG) ≥1.7 mmol/L or on drug treatment for high triglycerides, reduced
HDL cholesterol <1.03 mmol/L in men or <1.29 mmol/L in women or on drug treatment for
reduced HDL-C, elevated blood pressure ≥130 mmHg systolic BP or ≥85 mmHg diastolic
BP or on antihypertensive drug treatment for elevated BP, and elevated fasting glucose ≥5.6
mmol/L.9 Blood glucose, total cholesterol, LDL, HDL, triglycerides were measured from
fasting blood samples (Vitros, Johnson & Johnson, Rochester, NY), and blood pressure was
measured in the entire cohort annually. Waist circumference was measured at baseline and
at 6-yr follow-up.
Insulin Resistance—Insulin resistance was assessed at baseline using the homeostasis
model of insulin resistance (HOMA-IR), calculated as fasting insulin (uU/mL) (Abbott
Laboratories Diagnostics Division, South Pasadena, CA) × fasting glucose (mmol/L)/22.5.18
Covariates—BMI was calculated as weight (kilograms)/height squared (meters2).
Participants self-reported smoking status (current, past, or never) and alcohol intake
(categorized as 0–1, 2–7, or >7 drinks per week).
Medication use—Participants were asked to bring any medications taken over the
preceding 2 weeks to all study visits. Medications were classified using a hierarchical drug
dictionary based upon the Iowa Drug Information System.19
Statistical Analysis—Differences in baseline characteristics by MetS status were
assessed using x2-testfor categorical variables and t-test for continuous variables. For
continuous variables which did not follow a normal distribution, the appropriate non-
parametric test was employed.
The relationship between continuous TSH as a predictor of prevalent MetS at baseline and
incident MetS at 6-yr follow-up was determined using logistic regression. Potential
confounders such as age, sex, race, BMI, and HOMA-IR were chosen based on biological
plausibility and the published literature. We screened for additional confounders based on
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univariate association with MetS using a cutoff of p<0.1, which resulted in the inclusion of
smoking status as a covariate. Self-reported alcohol intake was a proposed covariate but was
excluded from our model as it was not independently associated with either thyroid function
(p=0.5) or MetS (p=0.5).
Univariate models were performed first and subsequently adjusted for age, sex and race.
Final multivariable models included age, sex, race, smoking status, BMI and HOMA-IR as
covariates. We then assessed for interaction with sex, race, and smoking status.
We used restricted cubic splines to flexibly model the association between TSH and MetS at
baseline, adjusted for age, sex, race, BMI, and HOMA-IR. The spline curve for the
probability of MetS vs. TSH level was plotted with 95% confidence intervals.
We determined the association between the categories of thyroid function (subclinical
hyperthyroid, euthyroid, subclinical hypothyroid, and overt hypothyroid) and the prevalence
of MetS at baseline and the incidence of MetS at 6-yr follow-up using the same covariates
described above. Subclinical hypothyroid participants were stratified by TSH level into two
categories: mild (TSH 4.5–9.9) and marked (TSH 10–20).
In addition to MetS as a composite endpoint, we also evaluated the association between
continuous TSH and thyroid function category with each individual component of MetS
using both logistic and linear regression. Triglycerides and HDL were natural-log
transformed for linear regression due to significant departure from the normal distribution.
Finally, in order to address the possibility of misclassification of thyroid function category
due to incomplete FT4 measurements in this cohort (FT4 was measured only in those with
TSH<0.1 or >7mIU/L), we performed a sensitivity analysis excluding any participants with
abnormal TSH who did not have measured FT4 (n= 216).
Data were analyzed using STATA 11 software (StataCorp, College Station, TX). All
analyses were confirmed by an independent analyst at the San Francisco Coordinating
Center (S.H.).
Results
Baseline Participants Characteristics
Characteristics of the participants are described in Table 1. The mean age of this cohort was
73.6 years (±2.9), and 53% were women.
Thyroid Function
Most (84%) of the individuals in our study were euthyroid. As previously reported, 2%
(n=50) had subclinical hyperthyroidism, less than 1% (n=21) had overt hypothyroidism and
nearly 13% (n=268) of individuals had subclinical hypothyroidism.17 TSH was significantly
associated with race, with higher mean TSH in White participants (mean TSH 3.2 vs. 2.2
mIU/L, p<0.01). Thyroid function was not associated with age, sex, weight or BMI (data not
shown).
Metabolic Syndrome
At baseline, 32% (n=684) of the cohort met criteria for MetS. Participants with prevalent
MetS were more likely to be female, White, and non-smokers. As expected, those with MetS
had higher mean blood pressure, abdominal circumference, triglycerides, fasting glucose,
HOMA-IR and lower HDL cholesterol. Individuals with MetS also had higher mean TSH,
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LDL and total cholesterol levels. Prevalent MetS was not associated with self-reported
alcohol intake or physical activity.
At 6-yr follow-up, among the 1032 individuals eligible for analysis there were 239 incident
cases of MetS. MetS developed in 20% (n=100) of men vs. 26% (n=139) of women, and in
24% (n=87) of Black vs. 23% (n=152) of White participants.
TSH and Metabolic Syndrome
TSH as a continuous variable was significantly associated with an increased odds of
prevalent MetS in an age, sex and race-adjusted model, with each one unit increase in TSH
predicting a 3% increase in the odds of MetS (OR 1.03, 95% CI 1.01–1.06, p=0.017). The
multivariable-adjusted odds ratio was similar (OR 1.03, 95% CI 1.01–1.06, p=0.018) (Table
2). Figure 1 shows the restricted cubic spline model of the association between TSH and
prevalent MetS, adjusted for age, sex, and race.
In order to evaluate the relationship between TSH and prevalent MetS within the euthyroid
range, we then restricted our analysis to include only normal TSH values (n=1,779). Among
euthyroid individuals, each one unit increase in TSH predicted an 18% increase in the odds
of MetS (OR 1.18, 1.06–1.32, p=0.002).
The association between continuous TSH and incident MetS was not significant (OR 1.00,
95% CI 0.96–1.04, p=0.92).
Thyroid Function Category and Metabolic Syndrome
Overall, there was no significant difference in the odds of prevalent MetS in subclinical
hypothyroid compared with euthyroid participants (OR 1.2, 95% CI 0.9–1.5, p=0.3) in
unadjusted or adjusted models. When levels of subclinical hypothyroidism were examined,
we found no evidence of association between mild subclinical hypothyroidism and the odds
of prevalent MetS. However, marked subclinical hypothyroidism (TSH 10–20) was
significantly associated with increased odds of prevalent MetS (OR 2.2, 95% CI 1.1–4.4,
p=0.02) after adjustment for age, sex, and race (Table 3). Multivariable analysis adjusted for
age, sex, race, smoking status, BMI, and HOMA-IR resulted in similarly increased odds of
prevalent MetS in participants with TSH 10–20 (OR 2.3, 95% CI 1.0–5.0, p=0.04).
Neither subclinical hyperthyroidism nor overt hypothyroidism was associated with prevalent
MetS.
In individuals with marked subclinical hypothyroidism (n=12), the odds of developing MetS
at 6-yr follow-up adjusted for age, sex, and race was similar to the odds of prevalent MetS
(OR 2.4, 95% CI 0.7–7.6, p=0.15) but did not achieve statistical significance (Table 4). The
confidence interval for this association was wide likely due to a small number of cases of
incident MetS among participants in this thyroid function category (n=5). Multivariable-
adjusted results were similar.
Thyroid Function Category and Individual Components of the Metabolic Syndrome
In order to determine which components of the metabolic syndrome were most strongly
associated with thyroid function, we evaluated the association of TSH and thyroid function
categories with each of the five MetS criteria at baseline (Table 5).
In an age, sex, and race-adjusted model, continuous TSH was significantly associated with
the odds of meeting the high triglyceride (OR 1.03, 95% CI 1.01–1.06, p=0.014) and low
HDL (OR 1.03, 95% CI 1.00–1.05, p=0.043) components of MetS. One unit increase in
TSH was associated with an approximately 1% increase in triglyceride levels (β=0.009, 95%
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CI 0.004–0.014, p=0.001). TSH was also marginally associated with decreasing HDL, with
each unit increase in TSH predicting a 0.3% decrease in HDL levels (β= −0.003, 95% CI =
−0.006–0.00, p=0.055). Although continuous TSH was associated with the odds of meeting
the elevated blood pressure criteria of the MetS (OR 1.04, 95% CI 1.00–1.07, p=0.032),
each unit increase in TSH did not predict a statistically significant increase in either systolic
or diastolic blood pressure. Neither continuous TSH nor categories of thyroid function were
associated with meeting the fasting glucose or waist circumference criteria of the MetS.
Subgroup analyses
There was no evidence of a differential effect of TSH on MetS between men and women
(p=0.48 for interaction), or between race groups (p= 0.36). There was also no evidence for
an interaction between TSH and smoking status (p=0.37). In addition, given the potential
relationship between serum TSH and obesity, we repeated our analyses separately in obese
participants (BMI>30 kg/m2). There was no significant difference in the association between
thyroid function and prevalent or incident MetS in participants with BMI ≤ or > 30 kg/m2
and testing for interaction by obesity status was not significant (p=0.37).
Additional Analyses
Several additional analyses were performed in order to determine the sensitivity of our
results to study inclusion and exclusion criteria. Since thyroid hormone users represented
nearly 10% of our included cohort (n=204) we repeated our analyses excluding these
individuals, although univariate models did not show an association between thyroid
hormone use and prevalent or incident MetS (p=0.2 and p=0.4, respectively). Among
participants who did not reported thyroid hormone use at baseline (n=1,915), we found that
continuous TSH was still associated with increased odds of prevalent MetS (OR 1.02, 95%
CI 1.00–1.06, p=0.057) but the association was no longer significant, likely due to loss of
power. Analysis restricted to the normal range of TSH values remained significant with each
unit increase in TSH predicting a 21% increase in the odds of MetS (OR 1.21, 95% CI 1.08–
1.35, p<0.01) (Table 2).
Excluding thyroid hormone users from the analysis of the association between thyroid
function categories and the odds of MetS at baseline substantially changed our results.
Marked subclinical hypothyroidism was no longer significantly associated with prevalent
MetS (OR 1.58, 95% CI 0.68–3.66, p=0.28). We also found that a greater proportion with
marked subclinical hypothyroidism were thyroid hormone users compared with all other
TSH categories except for subclinical hyperthyroidism. Thyroid hormone use was present in
8% of euthyroid participants, 9% with mild and 32% with marked subclinical
hypothyroidism, and 24% with overt hypothyroidism. Participants with subclinical
hyperthyroidism had the highest prevalence of thyroid hormone use (49%).
Exclusion of 182 participants with TSH 4.5–6.9 and 34 participants with TSH 0.1–0.35 who
were potentially misclassified due to lack of FT4 measurements did not substantially change
results. In analysis restricted to participants with complete thyroid function testing
(n=1,903), the odds of prevalent MetS (95% CI) for mild subclinical hyperthyroidism was
0.58 (0.15–2.16), for mild subclinical hypothyroid OR 0.93 (0.46–1.85), for marked
subclinical hypothyroid OR 2.34 (1.06–5.13), and for overt hypothyroid OR 0.97 (0.35–
2.63).
In our analyses of incident MetS, we initially included participants who developed incident
diabetes by year 6 (n=55). Analyses were repeated after excluding these individuals
(remaining cohort, n=977) and results were similar. Primary analyses also excluded
individuals with overt hyperthyroidism (n=4) as this represented a small number of
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participants who were likely to have variable thyroid function over time, however results
were unchanged with their inclusion.
Because BMI and HOMA-IR are potentially on the causal pathway between thyroid
function and MetS, their inclusion as covariates in multivariable models may have
attenuated our results. We therefore repeated analyses removing BMI and HOMA-IR from
our models and found similar results (for continuous TSH OR 1.03, 95% CI 1.00–1.06; for
marked subclinical hypothyroidism OR 2.24, 95% CI 1.13–4.46), suggesting the association
was not mediated by these factors.
Finally, we repeated our analyses using different cutpoints for categories of thyroid function.
Using the manufacturer’s assay (0.35–5.5mIU/L) or literature based (0.45–4.5mIU/L)
normal ranges 20 did not change our results (Data not shown).
Discussion
In a large population-based study of older adults, we found that increasing TSH levels were
associated with greater odds of prevalent metabolic syndrome. We also observed a
significant association between continuous TSH and prevalent MetS among euthyroid
participants. This suggests that even within the normal range, there may be a higher
prevalence of metabolic abnormalities as TSH levels increase. In addition, we found a
significant increase in the odds of prevalent MetS in participants with marked subclinical
hypothyroidism (TSH 10–20 mIU/L). This is the same category of individuals who, in a
recent meta-analysis by Rodondi et al, were found to have increased incidence of CHD
events and mortality, suggesting that cardiometabolic risk may be determined in part by
degree of TSH elevation.2
Although results for the association between continuous TSH and prevalent MetS were
unchanged after excluding thyroid hormone users, the relationship between marked
subclinical hypothyroidism and prevalent MetS was no longer statistically significant. This
suggests that our power to detect an association within this group may have been decreased
by excluding 11 of 34 participants (32%). Another possibility is that the observed
association among this group was due to the inclusion of under-treated overt hypothyroid
participants; therefore excluding these individuals attenuated the effect.
Previous cross-sectional studies have inconsistently found an association between MetS and
higher TSH levels or subclinical hypothyroidism.10, 11 This may be due to differences in
how thyroid function was categorized, the outcome assessed, and the age of participants
under study. In a Mexican cohort of over 3000 participants, Garduño-Garcia et al. reported a
relationship between FT4 and HDL, insulin and HOMA-IR levels, however there was no
difference in the prevalence of the MetS between euthyroid and subclinical hypothyroid
individuals.11 Of note, participants in this study with TSH values ≥10 mIU/L were classified
as overt hypothyroid regardless of FT4 level. This may have obscured an association
between subclinical hypothyroidism and MetS since we found a significant relationship only
in those with a TSH >10 mIU/L. In a cohort of 2700 euthyroid participants, Roos et al.
found an association between FT4 and 4 of the 5 MetS criteria, however this study did not
use MetS as a composite endpoint.10 In both of these studies, the average age of participants
(mean age 40’s) was much younger than the Health ABC, suggesting that age might play a
role in modifying the effect of TSH on the MetS and its components.
Two recent cross-sectional studies showed a positive association between TSH levels and
prevalent MetS. One study of a euthyroid German cohort (mean age 52) found that TSH in
the upper normal range (2.5–4.5 mIU/L) was associated with a 1.7-fold increased risk of
MetS compared with a low-normal TSH (0.3–2.5 mIU/L).12 Another study of nearly 1000
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euthyroid post-menopausal women in Korea (mean age 59) reported an odds ratio for MetS
of 1.9 in participants with the highest vs. lowest quartiles of TSH.13 In both studies only the
triglyceride component of MetS was independently associated with TSH. These finding are
consistent with our results, although we also found HDL levels to be weakly associated.
Current evidence suggests that many of the individual components of the metabolic
syndrome may be more prominent as TSH levels increase. Both the HUNT and Tromsø
studies reported a linear positive association between TSH levels and blood pressure among
euthyroid individuals which may be mediated by increased arterial stiffness and impaired
vascular smooth muscle relaxation.21–23 The HUNT study also found higher TSH to be
associated with higher triglycerides and lower HDL; furthermore, the relationship was
stronger among overweight individuals (BMI>25 kg/m2).24 Thyroid hormone may suppress
liver triglycerides synthesis, and there is increasing evidence that thyroid hormone increases
reverse cholesterol transport, thereby promoting HDL cholesterol activity.25 Increased
insulin resistance has also been documented in both overt and subclinical
hypothyroidism.26, 27
Insulin resistance is generally thought to be the underlying cause of the metabolic
syndrome.9 However, we did not find an association between thyroid function and insulin
resistance as measured by HOMA-IR or fasting glucose. The only individual components of
the metabolic syndrome independently associated with thyroid function were triglycerides
and HDL cholesterol. HDL cholesterol is an independent predictor of cardiovascular disease
even in individuals who are adequately treated for elevated LDL cholesterol.28, 29 Therefore
the association between thyroid function and HDL observed in our study might represent
one of the mechanisms by which subclinical hypothyroidism increases cardiovascular risk in
previous studies that adjusted for traditional CVD risk factors.
Several limitations of this study should be noted. First, TSH values were measured only
once despite previous data reporting spontaneous normalization of abnormal TSH in a
significant proportion of people.30, 31 This would likely result in non-differential
misclassification and attenuate our observations. In addition, FT4 levels were only measured
in participants with TSH values <0.1 or greater than 7.0 mIU/L which may have resulted in
misclassification of individuals with overt hyper- or hypothyroidism as having subclinical
disease, though studies of outpatient populations suggest that overt thyroid disease is rare
with mild TSH abnormalities.32 Furthermore, given the overall low prevalence of overt
hyper- or hypothyroidism in Health ABC participants with markedly high or low TSH
values (<1% for each condition),17 it is likely that few individuals were misclassified due to
a lack of complete FT4 measurements and a sensitivity analysis excluding these potentially
misclassified participants yielded similar results. Secondly, because only a small proportion
of the cohort had FT4 measurements (n=129), we were unable to evaluate the association
between FT4 and MetS.
The lack of significant association among individuals with overt hypothyroidism represents
an inconsistent finding of this study. Although the association between continuous TSH and
prevalent MetS was found to be linear, the odds ratios for prevalent disease in individuals
with overt hypothyroidism were not elevated. This may be due to the small number of
participants with overt hypothyroidism (n=21) and consequent lack of power.
In addition, there is some evidence that obesity itself may be responsible for elevated TSH
levels which are not indicative of thyroid dysfunction, but rather a consequence of greater
fat mass.33, 34 In obese individuals, increased adipose tissue may secrete greater amounts of
leptin, which in turn may stimulate the hypothalamic-pituitary-thyroid axis to secrete TSH.
Because of this bidirectional relationship, it is possible that in some participants obesity and
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MetS preceded the measurement of elevated TSH. However, we observed no correlation
between TSH and measures of obesity (BMI or waist circumference) and TSH values were
not significantly different between obese and non-obese participants (p=0.62). Furthermore,
results remained unchanged after adjustment for BMI, and analyses stratified by BMI≤ or
>30 kg/m2 were not significantly different. These results are in contrast to those reported by
Rotondi et al, who found significantly higher TSH values in euthyroid morbidly obese
(BMI>40) and obese (BMI>30) individuals versus normo-weight controls.35
Finally, our results showed an association between thyroid function and prevalent, but not
incident MetS, and causal relationships cannot be established from cross-sectional data.
Although our results for incident disease were not statistically significant, the point
estimates for the odds of incident MetS were similar to those for prevalent disease.
However, we were underpowered in this analysis due to the very small number or
participants with marked subclinical hypothyroidism (n=12).
In conclusion, we describe an association between higher TSH levels and increased
prevalence of the metabolic syndrome not only in those with abnormal thyroid function but
also within the euthyroid range. In addition, individuals with subclinical hypothyroidism and
TSH >10mIU/L may be at greater risk for MetS and its associated complications. The
relationship between thyroid function and MetS appears to be driven primarily by higher
triglycerides and lower HDL. Further prospective studies are needed to determine whether
treatment of elevated TSH can attenuate these metabolic abnormalities.
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Figure 1.
Fitted prevalence of metabolic syndrome as a function of TSH levels, with 95% confidence
interval, holding age, sex, race, BMI, smoking status, and HOMA-IR constant at their
sample means
Waring et al. Page 12
Clin Endocrinol (Oxf). Author manuscript; available in PMC 2013 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Waring et al. Page 13
Table 1
Baseline Characteristics of the Cohort
MetS+ (N= 684) MetS − (N= 1,435) P-value
Age, years 73.4 (2.8) 73.7 (2.9) 0.03
Sex (n) <0.01
 Male 280 (40.9) 712 (49.6)
 Female 404 (59.1) 723 (50.4)
Race (n)
 White 477 (69.7) 871 (60.7) <0.01
 Black 207 (30.3) 564 (39.3)
Weight, kg 79.6 (14.6) 71.6 (14.0) <0.01
BMI, kg/m2 29.0 (4.6) 25.9 (4.3) <0.01
Smoking (n) <0.01
 Current 49 (7.2) 165 (11.5)
 Never/Past 634 (92.7) 1,268 (88.4)
Alcohol Intake (n) 0.26
 0–1 drink/wk 328 (48.0) 652 (45.4)
 2–7 drink/wk 348 (50.9) 759 (52.9)
 >7 drink/wk 8 (1.2) 22 (1.5)
Weekly exercise (n) 22 (3.2) 37 (2.6) 0.40
SBP, mmHg 139.1 (19.9) 132.8 (20.8) <0.01
DBP, mmHg 72.4 (11.3) 71.1 (11.7) 0.02
Abdominal 104.4 (11.3) 95.2 (12.4) <0.01
Circumference, cm
TSH, mIU/L 2.4 (2.1)* 2.1 (1.8)* <0.01
Total Cholesterol, mmol/L 5.38 (1.03) 5.21 (0.96) <0.01
LDL Cholesterol, mmol/L 3.26 (0.93) 3.13 (0.86) <0.01
HDL Cholesterol, mmol/L 1.1 (0.36)* 1.48 (0.52)* <0.01
Triglycerides, mmol/L 1.90 (1.05)* 1.14 (0.55)* <0.01
Fasting Glucose, mmol/L 5.40 (0.57) 5.0 (0.44) <0.01
HOMA-IR 2.1 (1.6)* 1.3 (0.9)* <0.01
Data are given as mean (SD) or n(percent) unless otherwise noted.
For multilevel categorical variables, the P-value for test of trend is reported.
*
Median (interquartile range)
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Table 2
Odds Ratio of Prevalent MetS by TSH
TSH (per 1 unit increase) Age, Sex, & Race Adjusted OR (95% CI) Multivariable Adjusted OR* (95% CI)
Entire Cohort
 All TSH values (n=2119) 1.03 (1.01–1.06) 1.03 (1.01–106)
 Euthyroid range only (n=1779) 1.18 (1.06–1.32) 1.16 (1.03–1.30)
Excluding Thyroid Hormone Users
 All TSH values (n=1915) 1.03 (1.00–1.06) 1.03 (1.00–1.06)
 Euthyroid range only (n=1641) 1.21 (1.08–1.35) 1.14 (1.00–1.30)
*Adjusted for age, sex, race, smoking status, BMI, and HOMA-IR
Clin Endocrinol (Oxf). Author manuscript; available in PMC 2013 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Waring et al. Page 15
Table 3
Odds of Prevalent MetS at Baseline by Thyroid Function Category
Thyroid Function Category
Participants with MetS at Baseline, n
(%)
OR (95% CI)
Age, Sex, & Race Adjusted Multivariable Adjusted**
Subclinical Hyperthyroid 16/50 (32) 0.9 (0.5–1.7) 0.8 (0.4–1.6)
Euthyroid 561/1779 (32) Referent Referent
Mild Subclinical Hypothyroid* 80/234 (34) 1.0 (0.8–1.4) 1.0 (0.7–1.5)
Marked Subclinical Hypothyroid* 18/34 (53) 2.2 (1.1–4.4) 2.3 (1.0–5.0)
Overt Hypothyroid 8/21 (38) 1.1 (0.5–2.8) 1.0 (0.4–2.6)
*
Mild Subclinical Hypo = TSH 4.5–9.9 mIU/mL, Marked Subclinical Hypo = TSH 10–20 mIU/mL
**Adjusted for age, sex, race, smoking status, BMI, and HOMA-IR
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Table 4
Odds of Incident MetS at Year 6 by Thyroid function Category
Thyroid Function Category
Participants with MetS at 6yr Follow-Up,
n (%)
OR (95% CI)
Age, Sex, & Race
Adjusted Multivariable Adjusted**
Subclinical Hyperthyroid 5/21 (24) 1.0 (0.3–2.7) 0.8 (0.2–2.5)
Euthyroid 200/871 (23) reference
Mild Subclinical Hypothyroid* 27/117 (23) 1.0 (0.6–1.6) 1.2 (0.7–1.9)
Marked Subclinical Hypothyroid* 5/12 (42) 2.4 (0.7–7.6) 2.2 (0.6–7.5)
Overt Hypothyroid 2/11 (18) 0.6 (0.1–3.0) 0.6 (0.1–2.8)
*
Mild Subclinical Hypo = TSH 4.5–9.9 mIU/L, Marked Subclinical Hypo = TSH 10–20 mIU/L
**Adjusted for age, sex, race, smoking status, BMI, and HOMA-IR
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